do peptides help FAQ

Consider Cerebrolysin or Dihexa for neuroprotection and BDNF upregulation. CIRS brain fog often involves cytokine-induced hippocampal damage that doesn't resolve immediately when systemic inflammation drops. The neural tissue needs active repair. Cerebrolysin provides neurotrophic support through multiple growth factors; Dihexa enhances synaptic density and has shown cognitive improvements in animal models of neurodegeneration. Dosing: Cerebrolysin 30ml IV over 10 days, Dihexa 5–10mg oral daily. Neither replaces VIP nasal spray (which addresses MSH and hypothalamic dysfunction), but they target neuroplasticity pathways VIP doesn't directly affect.

Combination use is not well-studied. KPV and BPC-157 operate through pathways independent of TNF-α blockade, suggesting additive effects are theoretically possible without overlapping toxicity. However, no published trials have evaluated peptides combined with infliximab, adalimumab, or vedolizumab. The safety profile of peptides in isolation appears favourable. GI upset and injection site reactions are the primary reported side effects. But immunomodulatory peptides could theoretically interfere with biologic efficacy if they alter T-cell populations in unpredictable ways. If you're on a biologic, introducing peptides without prescriber oversight creates unquantified risk.

Add immune-modulating peptides like Thymalin to address persistent T-regulatory cell suppression. Many CIRS patients clear biotoxins and reduce inflammatory markers (C4a, TGF-beta-1) but remain symptomatic due to immune system retraining failure. The body stays locked in a pro-inflammatory state even after the trigger is removed. Thymalin's mechanism (enhancing thymic output of functional T-regs) directly targets that persistent dysregulation. Typical protocols run 10mg subcutaneous daily for 10–20 days, reassess inflammatory markers, then repeat cycles as needed. The peptide does not replace binders or VIP. It addresses a downstream immune failure that those treatments don't correct.

Peptide effects are dose-dependent and timeline-specific. If you're using standard BPC-157 dosing (250–500 mcg twice daily) and seeing no subjective improvement by day 10–14, verify three things: (1) peptide storage temperature. Was it refrigerated continuously since reconstitution? (2) Injection technique. Are you injecting subcutaneously (into fat layer) rather than intramuscularly? (3) Dosing consistency. Missed doses reduce tissue-level peptide concentrations significantly. Objective markers (reduced swelling, improved range of motion, less pain on movement) may precede subjective awareness. Compare week-two mobility to week-one baseline rather than expecting dramatic day-to-day changes.

Impure peptides either do nothing or produce unpredictable effects. Peptide synthesis requires exact amino acid sequencing. A single substitution changes the molecular structure and eliminates biological activity. We've tested peptides from unverified suppliers and found purity ranging from 60-85%, with some samples containing no active peptide at all. Real Peptides uses small-batch synthesis with third-party verification to guarantee >98% purity. The threshold where pharmacological effects match published research data.

You'll see some fat loss from lipolytic activation, but without the training stimulus to preserve muscle, you'll lose lean mass alongside fat. That's weight loss, not recomposition. GH and IGF-1 elevation can't prevent muscle protein breakdown if there's no mechanical tension signal telling the body to retain that tissue. A 2015 study in the American Journal of Physiology found that GH administration without resistance training produced no net change in lean mass despite elevated IGF-1 levels. Fat loss occurred, but so did muscle loss in a 1:1 ratio.

Administer peptides during the proliferation phase (weeks 1–6 post-injury) for maximum effect. BPC-157 and TB-500 work by accelerating processes already underway. Fibroblast migration, collagen synthesis, angiogenesis. If you're six months past injury and in the remodeling phase, peptides can still improve tissue organization and reduce scar tissue formation, but the largest gains occur when the body is actively rebuilding, not maintaining.

Start with growth hormone-releasing peptides rather than thyroid-targeted compounds. Chronic caloric restriction suppresses both GH pulsatility and thyroid conversion efficiency. GHRP protocols address the GH component first, often producing measurable REE increases within 4–6 weeks as measured by indirect calorimetry. Layer thyroid support (like thymalin) after establishing baseline GH responsiveness. Simultaneously, address the dietary component: reverse dieting at 50–100 calories per week while monitoring body composition prevents rebound fat gain while metabolic signaling normalizes.

Focus on peptides that enhance synaptic plasticity rather than those that prevent acute cell death. Acute neuroprotection (stroke, TBI) requires rapid intervention within the 6–12 hour excitotoxic window. Chronic neurodegeneration (Alzheimer's, Parkinson's) involves progressive synaptic loss, protein aggregation, and mitochondrial dysfunction over years. Dihexa shows efficacy in chronic models because it potentiates BDNF-TrkB signaling that supports ongoing dendritic remodeling. Not just emergency survival signaling. In 12-month-old APP/PS1 mice (late-stage pathology), 30 days of dihexa restored hippocampal synaptophysin expression to 90% of wild-type levels, while P21 showed no structural benefit in the same model (Neurobiol Aging, 2015). Match the peptide mechanism to the disease timeline.

Discard it. Peptides are proteins, and protein denaturation occurs irreversibly above 8°C for most formulations. Reconstituted peptides stored at room temperature for more than 2–4 hours lose structural integrity, meaning the peptide no longer binds to its target receptor even if it looks clear and unchanged. Appearance is not a valid potency indicator. Refrigerate immediately after reconstitution and never attempt to 're-refrigerate' a peptide that's been left warm. The damage is already done.

Consult a physician with peptide prescribing experience before purchasing or using any compound. Cerebrolysin requires intramuscular injection and medical oversight; self-administration without training risks injection site infections or improper dosing. Dihexa and P21 are research-grade compounds not approved for human use outside clinical trials. Purchasing them means you're participating in unregulated self-experimentation. If you're already on stimulant therapy and want to explore adjunctive peptides, frame it as a discussion about neuroplasticity support, not stimulant replacement.

Switch to TB-500 as the primary compound if the injury involves ligaments or tendons (ACL tear, patellar tendinopathy). TB-500 accelerates soft tissue healing by 30–35% in preclinical models through enhanced collagen alignment and reduced scar tissue formation. Dosing for acute injuries: 5mg intramuscular twice weekly for 6–8 weeks, starting within 2 weeks of injury. BPC-157 can be added at 250mcg daily if inflammation is significant, but TB-500 is the lead compound for fresh ligament damage.

This suggests either receptor downregulation (your body adapted to the peptide's signal) or the initial improvement addressed a secondary mechanism while the primary cause remains untreated. Peptides like Dihexa and Cerebrolysin don't typically cause tolerance within two weeks, so returning symptoms more likely indicate that neuroinflammation or mitochondrial dysfunction is still active. Consider rotating peptides or adding a complementary mechanism. For example, pairing Cerebrolysin with Thymalin to address both neuroplasticity and inflammation simultaneously.

This is where thymosin peptides show the most intriguing potential. Relapse in IBD often correlates with declining Treg function and loss of microbial tolerance. Thymosin alpha-1's ability to sustain elevated Treg levels suggests maintenance potential, but the longest human trial ran only 12 weeks. Nowhere near the years-long remission maintenance required to declare prevention efficacy. BPC-157 and KPV target active inflammation; their role in asymptomatic periods is unclear. No peptide has demonstrated relapse prevention in controlled trials.

Copper peptide formulations contain ionic copper (Cu²⁺) bound to the peptide sequence, not metallic copper. Allergic contact dermatitis to copper is exceedingly rare. Patch testing studies show true copper allergy in fewer than 2% of the population, and most reactions are to nickel-contaminated copper jewellery, not pure ionic copper. If you have a documented copper allergy confirmed by patch testing, avoid GHK-Cu formulations and use palmitoyl peptides instead. They deliver comparable barrier-repair effects through a different mechanism. If you're unsure, apply a test dose to the inner forearm and monitor for 48 hours before using on eczema-prone areas.

No. Severe eczema with EASI scores above 21 or failure of multiple topical therapies requires systemic immunomodulation that peptides can't provide. Biologics like dupilumab block the IL-4/IL-13 pathway that drives type 2 inflammation systemically, addressing disease activity that topical agents can't reach. Peptides work at the skin surface to repair barrier defects. They complement biologics but don't replace them. The optimal approach: use biologics to control systemic inflammation, then apply peptide-based topicals to accelerate barrier recovery and reduce long-term biologic dependence. Studies show patients on dupilumab who added barrier-repair peptides achieved remission 34% faster than those on dupilumab alone.

Check the formulation's peptide concentration and molecular weight. Most over-the-counter peptide creams contain 0.05–0.1% active peptide, which is below the threshold shown effective in trials (0.5–1% for copper peptides, 3–5% for palmitoyl peptides). Peptide stability also matters: GHK-Cu degrades rapidly in formulations above pH 6.5, and exposure to air or light denatures most peptide structures within weeks of opening. If you used a product stored improperly or formulated with insufficient active concentration, therapeutic failure was predictable. Consider research-grade peptide formulations like those available through Real Peptides. Precision synthesis ensures consistent potency and stability.

Verify your peptide concentration and formulation pH—most over-the-counter serums contain 0.1–0.5% copper peptide, below the 1–2% threshold shown effective in clinical trials. Check the product pH with litmus strips: peptides denature below pH 4.5 or above pH 7.5. If your serum is correctly formulated, reassess scar depth objectively using consistent lighting and photography—subtle improvements in shallow rolling scars often go unnoticed until week 12–16. Deep ice pick scars (>2mm depth) rarely respond to topical peptides alone and typically require procedural intervention like TCA CROSS or fractional CO2 laser combined with peptide aftercare.

No—peptides help with acne scars that are atrophic (depressed) by stimulating collagen synthesis. Hypertrophic scars and keloids result from collagen overproduction, so applying GHK-Cu or Matrixyl could worsen the condition by further upregulating procollagen synthesis. Hypertrophic scar protocols require MMP activation (not inhibition), corticosteroid injections, or silicone sheeting to flatten excess tissue. If you're uncertain whether your scars are atrophic or hypertrophic, assess texture: atrophic scars sit below surrounding skin; hypertrophic scars are raised above the surface.

No, but expectations must be calibrated. Mature striae albae have completed the scar maturation process. Fibroblast activity is minimal and collagen turnover is slow. Peptides can still signal new collagen synthesis, but the improvement ceiling is lower (12–18% versus 20–25% for fresh marks). You'll see modest texture improvement and slight pigmentation blending, but the width and depth of the scar won't change meaningfully. For marks older than 10 years, consider pairing topical peptides with microneedling or fractional laser to create controlled micro-injury that reactivates fibroblast response. Peptides applied immediately post-procedure show enhanced uptake.